Optimizing Gonadotropin-Releasing Hormone Agonist Therapy in Women with Endometriosis

Endometriosis is a highly prevalent disease among women of reproductive age. While many treatments are available, one of the most widely utilized is treatment with gonadotropin-releasing hormone (GnRH) agonists. These agents work by producing a profound suppression of gonadotropin secretion by the pituitary, resulting in a hypoestrogenic state and subsequent diminution of endometriosis lesions. The GnRH agonists on the market have been shown to work quite well in reducing all pain symptoms associated with endometriosis, including dysmenorrhea, dyspareunia, and noncyclic pelvic pain. However, there is no evidence to suggest that this treatment is of value in endometriosis-associated infertility. Conflicting data exist regarding the role of GnRH agonists in the treatment of endometriomas, but the bulk of the evidence suggests a low degree of efficacy. GnRH agonists are often initiated with the onset of menses, but a more rapid response is observed with mid-luteal administration. A limit of 6 months per treatment course is required due to loss of bone mineral density during therapy, but this can be extended via the addition of ‘add-back’ therapy. Such adjunctive regimens demonstrated to maintain efficacy and reduce adverse effects include progestogen alone or a low-dose combination of estrogen and progestogen. Retreatment with these drugs is supported by limited data. The use of GnRH agonists as surgical adjuncts has been studied by several investigators. Their use preoperatively has not been shown to be of value. Similarly, 3 months of postoperative administration has failed to enhance treatment. However, 6 months of postoperative GnRH agonists appear to improve the duration of relief of pain symptoms. Future studies will need to focus on the role of these agents when used for repeated courses, in young women, and in conjunction with assisted reproduction. Similar content being viewed by others

Palter SF, Olive DL. Reproductive physiology. In: Berek JS, editor. Novak’s gynecology. 12th ed. Baltimore (MD): Williams & Wilkins, 1996: 149-74 Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril 1990; 54: 419–27 Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial. N Engl J Med 1998; 318: 485–9 Goserelin depot versus danazol in the treatment of endometriosis: the Australian/New Zealand experience. Aust N Z J Obstet Gynaecol 1996; 31: 55–60 Chang SP, Ng HT. A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Chinese Med J (Taipei) 1996; 57: 431–7 Cirkel U, Oochs H, Schneider HPG. A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur J Obstet Gynecol Reprod Biol 1995; 59: 61–9 Crosignani PG, Gastaldi A, Lombardi PL, et al. Leuprorelin acetate depot versus danazol in the treatment of endometriosis: results of an open multicentre trial. Clin Ther 1992; 14Suppl. A: 29–36 Dmowski WP, Radwanska E, Binor Z, et al. Ovarian suppression induced with buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertil Steril 1989; 51: 395–400 Fraser IS, Shearman RP, Jansen RP, et al. A comparative treatment trial of endometriosis using the gonadotropin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust N Z J Obstet Gynaecol 1991; 31(2): 158–63 Adamson GD, Kwei L, Edgren RA. Pain of endometriosis: effects of nafarelin and danazol therapy. Int J Fertil Med Stud 1994; 39: 215–7 Wheeler JM, Knittle JD, Miller JD. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis: I. Efficacy results. Am J Obstet Gynecol 1992; 167: 1367–71 Dawood MY, Ramos J, Khan-Dawood FS. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil Steril 1995; 63: 1177–83 The Nafarelin European Endometriosis Trial Group (NEET). Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. Fertil Steril 1992; 57: 514–22 Rolland R, van der Heijden PF. Nafarelin versus danazol in the treatment of endometriosis. Am J Obstet Gynecol 1990; 162: 586–8 Kennedy SH, Williams IA, Brodribb J, et al. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990; 53: 998–1003 Rock JA. A multicenter comparison of GnRH agonist (zoladex) and danazol in the treatment of endometriosis [abstract]. Fertil Steril 1991; 56: S49 Shaw RW. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis: Zoladex Endometriosis Study Team. Fertil Steril 1992; 58: 265–72 Prentice A, Deery A, Goldbeck-Wood S, et al. Gonadotropin-releasing hormone analogues for pain associated with endometriosis (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 1999 Vercellini P, Trespidi L, Colombo A, et al. A gonadotrophin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60(1): 75–9 Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Obstet Gynecol 1999; 93: 51–8 Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001; 345: 266–75 Olive DL, Pritts EA. The treatment of endometriosis: a review of the evidence. Ann N Y Acad Sci 2002; 955: 360–72 Fedele L, Parazzini F, Radici E, et al. Buserelin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: a randomized clinical trial. Am J Obstet Gynecol 1992; 166: 1345–50 Surrey ES, Silverberg KM, Surrey MW, et al. Effect of prolonged GnRH agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril 2002; 78: 699–704 Schenken RS. Gonadotropin-releasing hormone analogs in the treatment of endometriomas. Am J Obstet Gynecol 1990; 162: 579–81 Takahashi K, Okada S, Okada M, et al. Prognostic application of magnetic resonance imaging in patients with endometriomas treated with gonadotropin-releasing hormone analogue. Hum Reprod 1996; 11: 1083–5 Batioglu S, Celikkanat H, Ugur M, et al. The use of GnRH agonists in the treatment of endometriomas with or without drainage. J Pakistan Med Assoc 1996; 46: 30–2 Muzii L, Marana R, Caruana P, et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Fertil Steril 1996; 65: 1235–7 Marana R, Vittori G, Campo S, et al. Operative laparoscopy for adnexal cystic masses in patients under 40 years of age. J Am Assoc Gynecol Laparosc 1994; 1: S20 Hornstein MD, Yuzpe AA, Burrey KA, et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 1995; 63: 955–62 Hornstein MD, Surrey ES, Weisberg GW, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol 1998 Jan; 91(1): 16–24 Brookoff D. Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease. South Med J 1994; 87: 1088–91 Hurst BS, Gardner SC, Tucker KE, et al. Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. JSLS 2000; 4: 97–101 Makarainen L, Ronneberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side-effects of gonadotropin-releasing hormone agonists without changing its efficacy in endometriosis. Fertil Steril 1996; 65: 29–34 Moghissi KS, Schlaff WD, Olive DL, et al. Goserelin acetate (zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998; 69: 1056–62 Lee PI, Yoon JB, Joo KY, et al. Gonadotrophin releasing hormone agonist (GnRHa) zoladex (goserelin) and hormonal add-back therapy in endometriosis: a 12 month study [abstract]. Fertil Steril 2002; 77: S23 Surrey ES, Voigt B, Fournet N, et al. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low dose norethindrone ‘add-back’ therapy. Fertil Steril 1995; 63: 747–55 Adamson GD, Heinrichs WL, Henzl MR, et al. Therapeutic efficacy and bone mineral density response during and following a three-month retreatment of endometriosis with nafarelin. Am J Obstet Gynecol 1997 Dec; 177(6): 1413–8 Hornstein MD, Yupze AA, Burry K, et al. Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density. Fertil Steril 1997; 67: 1013–8 Audebert A, Descampes P, Marret H. Pre or postoperative medical treatment with nafarelin in stage III-IV endometriosis: a French multicentered study. Eur J Obstet Gynecol Reprod Biol 1998; 79: 145–8 Parazzini F, Fedele L, Busacca M, et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 1994; 171: 1205–7 Hornstein MD, Hemmings R, Yuzpe AA, et al. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997 Nov; 68(5): 860–4 Vercellini P, Crosignani PG, Fedini R. A gonadotropin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 1999; 106: 672–7

The author has provided no information on sources of funding or on conflicts of interest that are directly relevant to the content of this review. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Olive, D.L. Optimizing Gonadotropin-Releasing Hormone Agonist Therapy in Women with Endometriosis. Mol Diag Ther 3, 83–89 (2004). https://doi.org/10.2165/00024677-200403020-00003 Published: Issue date: DOI: https://doi.org/10.2165/00024677-200403020-00003